Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses

Paul A Beavis; Nicole Milenkovski; Melissa A Henderson; Liza B John; Bertrand Allard; Sherene Loi; Michael H Kershaw; John Stagg; Phillip K Darcy

Journal article

Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses

Paul A Beavis, Nicole Milenkovski, Melissa A Henderson, Liza B John, Bertrand Allard, Sherene Loi, Michael H Kershaw, John Stagg, Phillip K Darcy

Cancer Immunology Research | AMER ASSOC CANCER RESEARCH | Published : 2015

DOI: 10.1158/2326-6066.CIR-14-0211

University of Melbourne Researchers

Phillip Darcy Author The Sir Peter MacCallum Department of Oncology

Sherene Loi Author The Sir Peter MacCallum Department of Oncology

Paul Beavis Author The Sir Peter MacCallum Department of Oncology

Michael Kershaw Author The Sir Peter MacCallum Department of Oncology

Related Projects (3)

Utilization Of Gene-Engineered T Cells For Enhancing Cancer Immunotherapy

Killer T lymphocytes can penetrate tumours and their transfer into cancer patients has demonstrated some encouraging results, but this form ..

Using The Immune System Against Cancer

My goal is to boost the immune system against cancer to develop new therapies. I aim to do this by genetically engineering the immune system..

Targeting The Adenosine Pathway For Enhancing Cancer Therapy

We have shown that drugs that block immunosuppressive adenosine receptors can improve anti-tumour immune responses and consequently enhance ..

Grants

Awarded by National Health and Medical Research Council (NHMRC)

Awarded by National Breast Cancer Fellowship

Awarded by NHMRC

Funding Acknowledgements

This work was funded by a Project Grant from the National Health and Medical Research Council (NHMRC; 1062580). P.A. Beavis was supported by a National Breast Cancer Fellowship (PF-14-008). P.K. Darcy and M.H. Kershaw were supported by NHMRC Senior Research Fellowships (1041828 and 1058388, respectively). J. Stagg was supported by an Operating Grant (Remodeling of the tumor microenvironment by CD73: a therapeutic target) from the Canadian Institutes of Health Research.